

Weili Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3174485/publications.pdf>

Version: 2024-02-01

73
papers

678
citations

687363

13
h-index

580821

25
g-index

74
all docs

74
docs citations

74
times ranked

1033
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation Induced Lymphopenia Is Associated With the Effective Dose to the Circulating Immune Cells in Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	10
2	Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2021, 156, 231-238.	0.6	26
3	MA13.01 A Validation Study on DNA Repair Gene Variant for Lung Cancer Survival Prediction after Chemoradiation: A Secondary Analysis for RTOG-0617 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, S181.	1.1	0
4	Significance of radiation esophagitis: Conditional survival assessment in patients with non-small cell lung cancer. <i>Journal of the National Cancer Center</i> , 2021, 1, 31-38.	7.4	1
5	Genetic Variations in the Transforming Growth Factor- β 1 Pathway May Improve Predictive Power for Overall Survival in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 599719.	2.8	4
6	Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC. <i>Radiotherapy and Oncology</i> , 2021, 162, 26-33.	0.6	10
7	A Validation Study on IDO Immune Biomarkers for Survival Prediction in Non-Small Cell Lung Cancer: Radiation Dose Fractionation Effect in Early-Stage Disease. <i>Clinical Cancer Research</i> , 2020, 26, 282-289.	7.0	19
8	A framework for modeling radiation induced lymphopenia in radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 144, 105-113.	0.6	26
9	FLASH Dose Rate Effect on Circulating Immune Cells: A Potential Mechanism for FLASH-RT?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, S7.	0.8	4
10	Genetic Variant in DNA Repair Genes May Be Associated with IDO Immune Status in Lung Cancer Patients Treated with Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, S172.	0.8	0
11	RTOG0617 to Externally Validate Blood Cell ERCC1/2 Genotypic Signature as a Radiosensitivity Biomarker for Both Tumor and Normal Tissue for Individualized Dose Prescription. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, S2.	0.8	3
12	Radiation Induced Lymphopenia is Associated with the Effective Dose to the Circulating Immune Cells (EDIC) for Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e57-e58.	0.8	1
13	Central Airway Toxicity After High Dose Radiation: A Combined Analysis of Prospective Clinical Trials for Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 587-596.	0.8	8
14	Weighted-Support Vector Machine Learning Classifier of Circulating Cytokine Biomarkers to Predict Radiation-Induced Lung Fibrosis in Non-Small-Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 601979.	2.8	7
15	Ultra-high dose rate effect on circulating immune cells: A potential mechanism for FLASH effect?. <i>Radiotherapy and Oncology</i> , 2020, 149, 55-62.	0.6	84
16	Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation. <i>Translational Lung Cancer Research</i> , 2020, 9, 2315-2327.	2.8	8
17	Changes of plasma GARP-LTG β 1 complex during chemoradiotherapy may predict survival in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21042-e21042.	1.6	0
18	The Effect of Thoracic Radiation Therapy on Overall Survival in SCLC: Findings from the National Cancer Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E549-E550.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Machine Learning to Build and Validate a Model for Radiation Pneumonitis Prediction in Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4343-4350.	7.0	16
20	P2.12-03 Building and Validating a Lymphocyte Nadir Based Model to Predict Survival in Patients with Limited Stage-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, S813.	1.1	1
21	Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, 213-219.	0.6	29
22	Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2019, 132, 241-249.	0.6	20
23	Coexpression patterns of IDO-1, PD-L1 and EGFR in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14279-e14279.	1.6	2
24	IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients. <i>Cancer Research</i> , 2018, 78, 809-816.	0.9	57
25	Radiation to the Immune System May be an Important Risk Factor for Long-term Survival after SBRT in Early Stage Non-small Cell Lung Cancer: A Role of RT Plan Optimization. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e689-e690.	0.8	2
26	Immune-related Cytokine Expression Predicts Survival in Early Stage Non-small Cell Lung Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e712.	0.8	0
27	Effect of Radiation Therapy Dose Fractionation on IDO Immune Status in Early Stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e711-e712.	0.8	0
28	The effect of thoracic radiation on overall survival and their association with systemic immune therapy in stage IV NSCLC: Findings from the National Cancer Database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9103-9103.	1.6	1
29	Racial disparities in non-small cell lung cancer, analysis of the Indiana University Cancer Center registry database 2000-2015.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18622-e18622.	1.6	1
30	Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1358.	7.1	177
31	Radiation to the Normal Lung May be an Important Risk Factor for Survival after Stereotactic Body Radiation Therapy in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E470-E471.	0.8	0
32	Risk Factors for Radiation-Induced Lung Toxicity after Stereotactic Body Radiation Therapy in Patients with Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E475-E476.	0.8	0
33	Factors Associated With Overall Survival After Radiation Therapy in Patients With Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E179.	0.8	0
34	Clinical Dose-Volume Histogram Analysis for Radiation-Induced Proximal Bronchial Tree Toxicity in Patients With Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E501.	0.8	0
35	Factors Associated With Survival in Patients With Non-Small Cell Lung Cancer from a Single Institution Study of 3569 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E508-E509.	0.8	0
36	Effects of Fractionation Schedule on Expression Patterns of Clinically Significant Circulating Cytokines During Radiation Therapy for Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E587-E588.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Effect of PTV and Collimator Margins on Tumor Control for Patients with Stage III Non-small Cell Lung Cancer in NRG Oncology RTOG-0617. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S181-S182.	0.8	1
38	MA 13.06 New Risk Factors for Overall Survival After SBRT in Early Stage NSCLC: A Role of RT Plan Optimization. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1853.	1.1	1
39	Principal component analysis identifies patterns of cytokine expression in non-small cell lung cancer patients undergoing definitive radiation therapy. <i>PLoS ONE</i> , 2017, 12, e0183239.	2.5	11
40	Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 3151-3155.	1.1	8
41	Postoperative radiation for tumor control and overall survival in thymic epithelial tumors (TET): A matched-pair analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8572-8572.	1.6	0
42	Paraneoplastic syndrome and survival in thymic epithelial tumors (TET): The Indiana University experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8574-8574.	1.6	0
43	A Phase II Trial of Midtreatment PET-CT Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E440.	0.8	1
44	Radiosensitive Patients Have Worse Survival After Stereotactic Body Radiation Therapy (SBRT)â€”Is Dose De-Escalation in SBRT Needed for These Patients?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E452-E453.	0.8	0
45	Radiation-Induced Proximal Bronchial Tree and Heart Toxicity After Stereotactic Body Radiation Therapy of the Thorax: Differences Between Central and Peripheral Diseases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E475-E476.	0.8	0
46	Cytokine Signature During Early Treatment May Predict Midtreatment Positron Emission Tomography/Computed Tomography and Survival in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E477.	0.8	0
47	Risk Factors for Noncancer Progressionâ€”Associated Death in Patients With Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E487-E488.	0.8	0
48	A Prognostic Model Combining Genetic Variations in the Transforming Growth Factor-Beta1 Pathway and Clinical Factors for Non-Small Cell Lung Cancer After Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E667.	0.8	0
49	Further study of circulating IgG antibodies to <sc>CD</sc>25â€”derived peptide antigens in nonsmall cell lung cancer. <i>FEBS Open Bio</i> , 2016, 6, 211-215.	2.3	3
50	Baseline Plasma Proteomic Analysis to Identify Glycoproteins for Prediction of Radiation Induced Lung Toxicity in Patients With Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, S151-S152.	0.8	0
51	Study of circulating IgG antibodies to BIRC5 and MYC in nonâ€”small cell lung cancer. <i>FEBS Open Bio</i> , 2015, 5, 809-812.	2.3	6
52	Use a survival model to correlate single-nucleotide polymorphisms of DNA repair genes with radiation doseâ€”response in patients with non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 77-82.	0.6	15
53	A Blood Biomarker Dependent Survival Model for NSCLC Patients Treated With Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S18.	0.8	1
54	A Blood Biomarker Dependent Survival Model for NSCLC Patients Treated With Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S77.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer. <i>Tumor Biology</i> , 2014, 35, 2047-2051.	1.8	19
56	Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer. <i>Tumor Biology</i> , 2014, 35, 4901-4905.	1.8	15
57	Autoantibodies Against p16 Protein-Derived Peptides Predict Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S665.	0.8	0
58	Pulmonary Artery Invasion, High-Dose Radiation, and Overall Survival in Patients With Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 313-321.	0.8	22
59	Assessing the Predictive Value of Cytokine Levels for Radiation-Induced Esophagitis in Combination With Clinical and Dosimetric Parameters in Patients Treated for Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S535.	0.8	0
60	Effect of Normal Lung Definition on Lung Dosimetry and Lung Toxicity Prediction in Radiation Therapy Treatment Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 956-963.	0.8	42
61	Serum MicroRNA Signature Predicts Survival in Patients With Unresectable/Inoperable Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S167.	0.8	0
62	FDG Pulmonary Uptake Changes During and Post-Radiation Therapy Compared to Pretreatment in Predicting Radiation-Induced Lung Toxicity in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S77.	0.8	1
63	Serum MicroRNA as a Predictive Marker for Radiation Pneumonitis in Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S93.	0.8	3
64	FDG Pulmonary Uptake Changes During and Postradiotherapy Compared to Pretreatment in Predicting Radiation-induced Lung Toxicity in Non-Small Cell Lung Cancer. <i>Practical Radiation Oncology</i> , 2013, 3, S22.	2.1	0
65	Serum miRNA signature to identify a patient's resistance to high-dose radiation therapy for unresectable non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7580-7580.	1.6	5
66	Circulating IgG antibody against FOXP3 may be a potential biomarker for lung cancer. <i>Advances in Lung Cancer (Irvine)</i> , 2013, 02, 79-83.	0.2	2
67	Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-small Cell Lung Cancer: A Systemic Review and Meta-analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S611-S612.	0.8	1
68	Single Nucleotide Polymorphisms in DNA Repair Genes May Be Associated With Survival in Patients With Non-small Cell Lung Cancer Treated With Definitive Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S69.	0.8	2
69	Relationship Between Pulmonary Artery Invasion and High-dose Radiation and Overall Survival in Patients With Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S612.	0.8	1
70	AB022. PS01.04. Myasthenia gravis in thymic epithelial tumors incidence and prognosis. <i>Mediastinum</i> , 0, 1, AB022-AB022.	1.1	0
71	AB006. OS01.06. Factors associated with survival in patients with thymoma: study of 523 cases from one institution. <i>Mediastinum</i> , 0, 1, AB006-AB006.	1.1	0
72	AB012. OS03.02. Paraneoplastic syndrome and survival in thymic epithelial tumors the IU experience. <i>Mediastinum</i> , 0, 1, AB012-AB012.	1.1	0

#	ARTICLE	IF	CITATIONS
73	AB001. OS01.01. Post op radiation may be detrimental in thymoma but not in thymic carcinoma tumors. Mediastinum, 0, 1, AB001-AB001.	1.1	0